arznei-telegramm® 01/2017 |
SPOT ON |
Hawthorn and Gingko biloba: protection of the status quo hampers adaptation to current knowledge |
THERAPY FROM A CRITICAL VIEWPOINT |
Duration of antibiotic treatment for community-acquired pneumonia |
Haemorrhoids: traditional excisional surgery is superior |
a-t READERS QUESTIONS AND COMMENTS |
Do proton pump inhibitors increase cardiovascular risk? |
Coloured urine caused by food |
IN BRIEF |
Zoledronic acid (ZOMETA, generics) for bone metastases: is a longer treatment interval possible without loss in efficacy? |
Are drugs for ALZMEIMER's disease soon no longer reimbursed in France? | Diethylstilbestrol (DES; in the past e.g. CYREN): harmful effects over three generations |
CURRENT ADR NETWORK REPORT |
Renal failure with levetiracetam (KEPPRA, generics) |
SIDE EFFECTS |
Vasculitis and lichen planus with denosumab (PROLIA, XGEVA)? |
Rebound: multiple vertebral fractures following discontinuation of denosumab (PROLIA) |